IMPACT OF PHARMACOKINETICS ON THE RISK ASSESSMENT OF DICHLOROMETHANE

On this page:

Overview
Downloads

Alert
Notice - This site contains archived material(s)

Archive disclaimer
Archived files are provided for reference purposes only. The file was current when produced, but is no longer maintained and may now be outdated. Persons with disabilities having difficulty accessing archived files may contact the Risk Webmaster for assistance. Please use the contact us form if you need additional support.

Abstract

The paper recapitulates the means by which a physiologically based risk assessment for dichloromethane (DCM, methylene chloride) evolved. Two somewhat different physiologically based pharmacokinetic (PBPK) models had been published by Angelo et al. in 1984 and Andersen et al. in 1987. The paper discusses the rationale for the selection and implementation of a PBPK model for purposes of estimating the delivered or effective dose. Also discussed is the rationale used for selecting the scaling method for estimating the equivalency of delivered dose between test species and humans.

Citation

Blancato, J. AND L. Rhomberg. IMPACT OF PHARMACOKINETICS ON THE RISK ASSESSMENT OF DICHLOROMETHANE. U.S. Environmental Protection Agency, Washington, D.C., EPA/600/D-88/219 (NTIS PB89173249), 1988.

Download(s)